HER2 Support Group Forums - View Single Post

Jean · 03-06-2009, 02:59 PM

Adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years. (American Society of Clinical Oncology [ASCO] guidelines include narrative rankings) (ASCO)

http://www.qualitymeasures.ahrq.gov/...1&doc_id=12039

I think you have to be ER positive by 4% to be considered for AI...but I am not sure...Becky knows much on this....
I am sure she can offer some solid advice.

Jean

03-06-2009, 02:59 PM	#2
Jean Senior Member Join Date: Oct 2005 Location: New Jersey Posts: 3,154	Some information.... Adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years. (American Society of Clinical Oncology [ASCO] guidelines include narrative rankings) (ASCO) http://www.qualitymeasures.ahrq.gov/...1&doc_id=12039 I think you have to be ER positive by 4% to be considered for AI...but I am not sure...Becky knows much on this.... I am sure she can offer some solid advice. Jean __________________ Stage 1, Grade 1, 3/30/05 Lumpectomy 4/15/05 - 6MM IDC Node Neg. (Sentinel node) ER+ 90% / PR-, Her2+++ by FISH Ki-67 40% Arimidex 5/05 Radiation 32 trt, 5/30/05 Oncotype DX test 4/17/06, 31% high risk TOPO 11 neg. 4/06 Stopped Arimidex 5/06 TCH 5/06, 6 treatments Herceptin 5/06 - for 1 yr. 9/06 Completed chemo Started Femara Sept. 2006